Hsp receptors: the cases of identity and mistaken identity.
Immune responses elicited by Hsps have been harnessed for the therapy of cancer. Hsps may also play a physiological role in the transfer of antigens in the form of peptides between cells during the event known as cross priming. To elicit these immune responses, Hsps engage antigen-presenting cells through their cell surface receptors. Various molecules have been suggested as Hsp receptors since their existence was first proposed 13 years ago. This review critically examines the literature on Hsp receptors and highlights the experimental evidence that has been provided or is lacking for each molecule. Two phase III clinical trials conducted with Hsp-based vaccines in patients with melanoma or renal cell carcinoma are also discussed.
Binder
Robert J
RJ
University of Pittsburgh School of Medicine, E1051, BSTWR, Department of Immunology, 200 Lothrop Street, Pittsburgh, PA 15261, USA. rjb42@pitt.edu
D000938:Antigen-Presenting Cells / Q000276:immunology; D006360:Heat-Shock Proteins / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy
D006360:Heat-Shock Proteins